Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7872429 | 0.91 | MAPT (0.57) | TSHRMAPTLMNAUSP2EPHX2 | |
| SCHEMBL16994744 | 0.86 | TSHR (0.54) | TSHRMAPTLMNAUSP2HTT | |
| SCHEMBL12846472 | 0.86 | TSHR (0.57) | TSHRMAPTLMNAUSP2HTT | |
| SCHEMBL12636528 | 0.84 | TSHR (0.59) | TSHRMAPTLMNAHTTKDM4E | |
| SCHEMBL14602602 | 0.84 | CNR1 (0.62) | TSHRMAPTLMNAEPHX2KDM4E | |
| SCHEMBL12813152 | 0.84 | KMT2A (0.58) | TSHRUSP2HTTKDM4ECNR1 | |
| SCHEMBL19657218 | 0.83 | MAPT (0.59) | TSHRMAPTLMNAEPHX2HTT | |
| SCHEMBL18311852 | 0.83 | MEN1 (0.59) | TSHRMAPTLMNAUSP2EPHX2 | |
| SCHEMBL16379735 | 0.82 | MAPT (0.57) | TSHRMAPTEPHX2KDM4ECNR1 | |
| SCHEMBL18354481 | 0.82 | ERN1 (0.57) | TSHRMAPTLMNAUSP2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024033280-A1 | FUROPYRIDIN AND FUROPYRIMIDIN, INHIBITORS OF PI4K, FOR USE IN THE TREATMENT OF PARASITE INFECTION AND MALARIA | MERCK PATENT GMBH (DE) | 2024-02-15 | — | — | WO | disclosed |
| EP-3218375-B1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| EP-2729150-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9161924-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | AMOREPACIFIC CORPORATION (KR) | 2013-06-20 | — | — | US | disclosed |
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | AMOREPACIFIC CORPORATION (KR) | 2013-06-20 | — | — | US | disclosed |
| WO-2012030170-A2 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | (주)아모레퍼시픽 (KR) | 2012-03-08 | — | — | WO | disclosed |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| WO-2011025565-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | TSHR 2827/4885MAPT 3534/4885LMNA 95/4885 |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | TSHR 2007/4885MAPT 3621/4885LMNA 3954/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | TSHR 3168/4885MAPT 2247/4885LMNA 4121/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | TSHR 2979/4885MAPT 2039/4885LMNA 4289/4885 |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | TSHR 2047/4885MAPT 1179/4885LMNA 2019/4885 |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ABL1, CDKN1A, MAP3K13 | TSHR 2081/4885MAPT 3206/4885LMNA 4433/4885 |
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | CNR1, CNR2, GPR18 | TSHR 2409/4885MAPT 2617/4885LMNA 4241/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | TSHR 2007/4885MAPT 3621/4885LMNA 3954/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | TSHR 2007/4885MAPT 3621/4885LMNA 3954/4885 |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | TSHR 2827/4885MAPT 3534/4885LMNA 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.